Therapeutic Area

Bisphosphonate

Therapeutic area intelligence for Bisphosphonate with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

Aurobindo Pharma →

Teva →

Assets

Aurobindo →

FDA →

Recent signals(2)

RegulatoryJune 23, 2026

FDA Grants AP Status for Teva's Risedronate Sodium Supplement

Teva Pharmaceuticals has received an Abbreviated Approval (AP) for a supplement of Risedronate Sodium.

StrategyJune 23, 2026

Aurobindo Pharma's Risendronate Sodium ANDA Submission Receives AP Status

Aurobindo Pharma's ANDA for Risendronate Sodium has been granted Abbreviated Approval (AP) status by the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.